Medela Inc. announced today it has filed a Notice of Appeal of a portion of the decision of the U.S. District Court for the Western District of Texas in litigation brought by Kinetic Concepts, Inc. (NYSE: KCI). That decision included a favorable judgment that Medela was not liable for infringing the KCI patents at issue. Medela will appeal those portions of the decision that rejected its contentions that the KCI patents are invalid and unenforceable.
“Medela continues to be committed to providing greater choice to patients and the healthcare professionals in the negative pressure wound therapy (NPWT) marketplace. One step towards achieving this is pursuing this appeal,” said Roman Kupper, CEO, Medela Healthcare. “We want to clarify the situation so we can continue our heritage of being a trusted, customer-focused manufacturer of high-quality, innovative and research-based products.”
Medela recently took another step in providing greater choice in the NPWT market with the launch of its Invia® Healing System. A key feature of the FDA-cleared system is its infection-preventing dual mechanism, which includes antimicrobial properties and active drainage to aid in controlling infection.
About Medela:
Medela, a privately held company, operates in the fields of Medical Technology and Breastfeeding for use by patients and healthcare professionals across a wide range of therapies and care settings. Medela focuses on providing research-based innovations for its customers. Medela, headquartered in Switzerland, serves customers through its 12 subsidiaries and a worldwide network of distribution partners in more than 90 countries. For more information, visit http://www.medelasuction.com/
